Universal Biosensors refuses to deny acquisition rumours
13 September, 2010 by David BinningResponding to reports in ALS last Friday that his company may be on the market, Univeral Biosensors chairman and interim CEO Andy Denver said today that “we are always up for sale”.
Novogen to sell isoflavone portfolio to Marshall Edwards
09 September, 2010 by David BinningAustralian drug development company Novogen announced today that it has agreed to sell the rights to its entire isoflavone portfolio to US subsidiary Marshall Edwards in return for stock.
New policy framework needed for medical research: Research Australia
08 September, 2010 by David BinningResearch Australia will next month to unveil a major new policy framework which it hopes will lead to more investment and greater collaboration around medical research in Australia.
Broadvector to raise $8.5m for prostate cancer and loose prosthetics
07 September, 2010 by David BinningAged health specialist Broadvector has issued a prospectus as it seeks to raise around $8.5 million to fund the development of a novel prostate cancer therapy in addition to a treatment addressing the problem of ascpetic loosening of hip replacements.
Market report: ASX posts strong week following robust economic data
03 September, 2010 by David BinningThe Australian Stock Market finished up for the week today, ending several weeks of losses, as investors warmed to the positive outlook for the local economy.
Halcygen reports maiden profit
01 September, 2010 by Staff WritersAntibiotic developer Halcygen Pharmaceuticals today reported a maiden net profit of $3.25 million for the year ended June 30, 2010, largely driven by the company’s acquisition of Mayne Pharma International late last year from Hospira Inc.
Market report: Healthcare index outperforms wider market
27 August, 2010 by David BinningThe Australian stock market just clawed its way into positive territory today as investors defied the prevailing gloom surrounding the US economy, although it wasn’t enough to snap a three-week losing streak.
China and India pharma companies driving M&A activity in Asia
27 August, 2010 by Staff WritersA report by analyst group Datamonitor has identified China and India’s pharmaceutical industries as the ones to watch following a flurry of M&A activity over the last three years.
Clinuvel identifies potential new target for Scenesse
25 August, 2010 by David BinningMelbourne biotech Clinuvel announced today that it plans to conduct clinical trials of its UV protection drug Scenesse as a treatment for the skin pigmentation disorder vitiligo.
Cellestis reports FY net profit up 26 percent
24 August, 2010 by Staff WritersMelbourne biotech Cellestis this week announced a full year net profit of $10.22 million, following strong growth in all of the company’s major markets.
Market report: ASX down amid renewed global concerns while election hangs on a knife edge
21 August, 2010 by David BinningThe Australian stock market finished down today amid renewed concerns about the pace of the global economic recovery and as local investors await the outcome of tomorrow’s federal election, which has become too close to call.
CSL announces profit dip and $900m share buyback
18 August, 2010 by Staff WritersCSL, Australia’s biggest biotech and the world’s second largest producer of plasma blood products, today reported an eight percent dip in full year net profit to $1.05 billion, as a rising Australian dollar dented overseas revenues.
2Fr solid-state wireless pressure catheter
17 August, 2010 by Staff WritersMillar Instruments and Telemetry Research have set a new standard for telemetry research by developing the TRM53P.
Aspen to buy Sigma Pharmaceuticals' drug division for $900m
17 August, 2010 by David BinningTroubled drug developer and healthcare provider Sigma Pharmaceuticals finally put an end to months of speculation today declaring that it would recommend shareholders accept an offer from Aspen Pharmacare to buy its pharmaceuticals business for $900 million.
Mesoblast progressing towards Phase 3 trial bone marrow trial in US
16 August, 2010 by Staff WritersRegenerative medicine specialists Mesoblast today announced that it has provided market guidance to the FDA regarding its Phase 3 bone marrow transplantation program, which it hopes will create more options for patients as well as a reduction in incidences of graft-versus-host disease (GVHD).
